Calidi Biotherapeutics, Inc./$CLDI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
Ticker
$CLDI
Sector
Primary listing
AMEX
Employees
28
Headquarters
Website
CLDI Metrics
BasicAdvanced
$5.8M
-
-$33.66
1.16
-
Price and volume
Market cap
$5.8M
Beta
1.16
52-week high
$7.25
52-week low
$1.61
Financial strength
Current ratio
1.13
Quick ratio
0.986
Long term debt to equity
87.62
Total debt to equity
193.208
Interest coverage (TTM)
-37.62%
Profitability
EBITDA (TTM)
-19.527
Effective tax rate (TTM)
-0.04%
Management effectiveness
Return on assets (TTM)
-158.23%
Return on equity (TTM)
414.22%
Valuation
Price to book
0.66
Price to tangible book (TTM)
0.66
Price to free cash flow (TTM)
-0.052
Free cash flow yield (TTM)
-1,917.18%
Free cash flow per share (TTM)
-32.586
Growth
Earnings per share change (TTM)
-54.87%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Calidi Biotherapeutics, Inc. stock?
Calidi Biotherapeutics, Inc. (CLDI) has a market cap of $5.8M as of August 23, 2025.
What is the P/E ratio for Calidi Biotherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Calidi Biotherapeutics, Inc. (CLDI) stock is 0 as of August 23, 2025.
Does Calidi Biotherapeutics, Inc. stock pay dividends?
No, Calidi Biotherapeutics, Inc. (CLDI) stock does not pay dividends to its shareholders as of August 23, 2025.
When is the next Calidi Biotherapeutics, Inc. dividend payment date?
Calidi Biotherapeutics, Inc. (CLDI) stock does not pay dividends to its shareholders.
What is the beta indicator for Calidi Biotherapeutics, Inc.?
Calidi Biotherapeutics, Inc. (CLDI) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.